Eko harnesses the power of smartphones and cloud data for monitoring patients with cardiovascular diseases. It has built a platform of non-invasive cardiovascular monitoring devices, clinical software, and point-of-care decision support algorithms to improve the delivery of cardiovascular care. In 2015, Eko launched the Eko Core Digital Stethoscope, the first FDA-cleared digital stethoscope on the market to wirelessly stream heart and lung sound to HIPAA-compliant software. For the first time in history, patient sounds can be integrated with electronic health records (EHRs) for more seamless referrals, documentation, and monitoring. Eko was established in 2013 and is based in Berkeley, California.
Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.
Curve Health, Inc. is an innovative online platform focused on enhancing senior care through a combination of telemedicine, health information exchange, predictive analytics, and smart billing. Established in 2020 and headquartered in New York, the platform allows physicians to provide remote care to patients in skilled nursing facilities, at home, or during transportation. By integrating these technologies, Curve Health has significantly reduced patient transfers from skilled nursing facilities to emergency departments by over 50%. The platform aims to streamline healthcare delivery, optimize staff allocation, and minimize readmissions while improving care quality and ensuring a seamless patient experience. Additionally, it facilitates efficient communication between hospital systems and post-acute facilities, accelerating reimbursements and enabling effective tracking of patient diagnoses and outcomes.
Casana is a healthcare technology company focused on heart health monitoring. It has developed the Heart Seat, an innovative product that integrates a toilet seat with a cardiovascular monitoring system. This device allows patients to conveniently track essential heart health metrics such as heart rate, blood pressure, cardiac output, ECG, and blood oxygenation from the comfort of their homes. The Heart Seat operates on a cloud-connected platform, enabling seamless data capture and analysis. Founded in 2018 and based in Rochester, New York, Casana aims to enhance heart health monitoring by providing a user-friendly solution that minimizes the need for active patient engagement.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.
Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Ieso Digital Health Ltd. specializes in providing online evidence-based cognitive behavioral therapy (CBT) to individuals facing various mental health challenges, including anxiety and depression. The company's unique online service facilitates real-time communication between accredited therapists and patients through a secure virtual environment, where sessions are conducted via text. This approach not only mirrors traditional face-to-face interactions but also offers greater convenience for users. Ieso began its operations in the UK in 2000 and has since expanded into the US market, collaborating with Medicaid and commercial health plans to enhance access to mental health services. The company’s therapy model has demonstrated effectiveness, requiring fewer sessions to achieve recovery and showing improved outcomes compared to conventional therapy methods. Ieso serves a diverse clientele, including health providers, private individuals, and businesses, and is recognized for its rapid growth in the digital health sector.
Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.
Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in the development and manufacturing of advanced genetic sequencing technology and diagnostic equipment. Founded in 2016, the company offers a variety of genome extraction kits, including those for stool, blood, saliva, and bacteria. Axbio's product line also encompasses sequencing and diagnostic systems, disposable biochips, and reagents. The company employs semiconductor nanotechnology in its biochips for rapid molecular in-vitro diagnostics and utilizes a microfluidic Bio-CMOS platform for high-throughput sequencing. Axbio's capabilities extend from low-cost handheld devices for bedside diagnostics to fully automated instruments suitable for independent laboratories and hospitals, facilitating services such as early cancer screening, rapid pathogen detection, and drug development. The company is currently operating in stealth mode.
Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.
MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, utilizing sensors, music, and artificial intelligence to enhance therapeutic outcomes. Founded in 2015 and headquartered in Portland, Maine, the company focuses on patients affected by conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. MedRhythms develops evidence-based interventions aimed at improving walking, speech, cognitive abilities, and overall functional outcomes through the intersection of music and neuroscience. By employing innovative technology and direct brain stimulation techniques, the company aims to provide effective rehabilitation solutions that leverage the therapeutic benefits of music for neurological recovery.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
Linus Health, Inc. is a company based in Waltham, Massachusetts, that specializes in brain health monitoring through a digital platform. Founded in 2019, Linus Health develops a mobile application and online platform that collects various digital measurements, including voice, speech, gait, cognition, and eye movement. The platform is designed to facilitate the detection, diagnosis, and treatment of cognitive and mental health conditions. Additionally, it provides clinical decision support and care planning tools, enabling early detection of brain health issues and offering healthcare providers actionable recommendations for patient care. The company's mission is to transform brain health for individuals worldwide through innovative technology.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
AliveX is a developer of an AI-driven immunology platform that focuses on biomarker discovery for early cancer screening, precision medicine, and treatment monitoring. By integrating multi-omics data, artificial intelligence, and computational biology, the platform aims to decode the human immune system. This innovative approach enables collaboration with leading clinicians, research institutions, and pharmaceutical companies to address significant clinical challenges. AliveX's efforts are directed towards transforming life sciences research and advancing the next generation of precision diagnostics and treatments in the field of immunology.
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
Medbanks Network Technology Co. Ltd., founded in 2014 and headquartered in Beijing, China, provides data processing services tailored for the healthcare industry. The company specializes in developing a multi-center database that aggregates and analyzes data reflecting China's patient population. Additionally, Medbanks creates an oncology database that incorporates clinical and professional medical services based on information collected from hospitals. This focus on data management and analysis aims to enhance healthcare services and research in China.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Beijing Naxions Technology Co., Ltd. is a healthcare-focused company that specializes in providing digital marketing services tailored for the pharmaceutical industry. Founded in 2014 and headquartered in Chaoyang District, China, with additional offices in Shanghai, Naxions has developed a software-as-a-service (SaaS) platform designed to enhance pharmaceutical sales management. The platform offers a range of services, including data capture, cleaning, and analysis, alongside features for content sharing and project management. By leveraging internet technology, Naxions aims to support pharmaceutical enterprises in developing their brand image and increasing market awareness through real-time data analysis and visualization.
Prescryptive Health, Inc. is a digital health company based in Redmond, Washington, that operates a prescription benefits platform aimed at enhancing accessibility, affordability, and personalization in the medication market. Established in 2017, the company provides a range of services, including the analysis of existing plan designs, recommendations for new plans, and assistance with member enrollment. Its platform offers users, including employers, health plans, providers, pharmacies, and pharmaceutical companies, direct access to unbiased market pricing and essential information about prescribed treatments. This enables patients to understand their out-of-pocket expenses, insurance coverage, and available lower-cost alternatives at the point of care, thereby promoting informed decision-making in the prescription drug market.
neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
Boohee provides you with tailor-made weight loss programs, simple and effective weight loss tools, supplemented by slimming courses, weight loss forums and food calorie enquiries, so that you are thin and healthy, thin and beautiful!
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, focused on developing digital diagnostic and therapeutic solutions for children at risk of developmental delays, including autism. The company's online application allows parents and caregivers to assess and monitor their child's cognitive development through a series of behavioral questions and a brief video recording of the child at play. This process generates scores and personalized recommendations, helping families understand their child's risk for developmental disorders and facilitating communication with healthcare providers. By utilizing responsible artificial intelligence, Cognoa aims to identify subtle signs of developmental delays and support informed clinical diagnoses. Its products are designed to be routinely prescribed by pediatricians and are intended to improve the standard of care for diagnosing and treating behavioral health conditions in children.
Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.
ZielBio, Inc. is a biotechnology company focused on identifying high-value disease targets and developing therapeutic interventions to enhance patient outcomes. The company is based in Charlottesville, Virginia, and utilizes its proprietary drug discovery platform, Zielfind, which integrates functional high-throughput screening with large content data analytics to pinpoint valuable targets. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody designed to target cell surface plectin, a significant player in various cancers including ovarian, pancreatic, lung, and colorectal cancer. Founded in 2010, ZielBio aims to transform disease treatment through innovative therapeutic approaches.
Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that focuses on developing applications for monitoring brain health. The company has created a multi-modal brain health analytics platform that utilizes advances in artificial intelligence, neuroscience, and speech analytics to detect changes in neurological health. By leveraging proprietary metrics, Aural Analytics transforms smartphones and tablets into effective brain health monitors, capturing subtle, clinically relevant aspects of a patient's condition through speech samples. This technology enhances traditional functional rating scales used in clinical trials by providing objective, continuous outcomes, thereby allowing for more reliable evaluations of drug efficacy and other interventions. Aural Analytics' platform aims to reveal incremental changes in neurological health, facilitating accurate assessments by medical professionals.
Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.
Hangzhou Yunhu Technology Group Co.,Ltd develops an Internet platform for primary medical services in China. It offers a series of platform-based testing products; and a SaaS based LIS\HIS platform, designed for local medication institutions. It also provides a third party cold chain logistic services to support the blood and drug delivery. The company was founded in 2017 and is based in Hangzhou, China.
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
GeneDock, founded in September 2014, is a national high-tech enterprise specializing in precision medical data technology. The company develops and provides a comprehensive SaaS platform that allows users to extract, analyze, and visualize medical records, facilitating improved research and studies for medical and scientific institutions. With industry-leading expertise, GeneDock has successfully built data platforms for numerous prominent facilities, including top three hospitals and leading industry organizations in China. The core team comprises members with backgrounds from renowned companies, and the firm has attracted investment from notable institutions. GeneDock aims to drive innovation in healthcare through advanced data technology solutions.
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
Ins Health operates a comprehensive technology platform dedicated to innovating health insurance products. This platform integrates medical and insurance big data to enhance the risk assessment and competitiveness of health insurance offerings. Ins Health's model includes various components such as product innovation services, online intelligent underwriting, medical management, intelligent claims processing, and health management. The company has played a significant role in advancing mid-end medical insurance, million medical insurance, elderly cancer prevention insurance, and patient medical insurance. By establishing a micro-ecology framework for health insurance, Ins Health aims to streamline and improve the overall efficiency of health insurance processes.
Ishen365 develops and operates renal care service platform for healthcare sector. It provides chronic disease management solutions for patients with kidney disease. The company is based in Shanghai, China.
Provider of an online health management service platform intended to offer third-party health management services to large and medium-sized enterprises. The company's platform include services like file recording, health assessment, health intervention and health related education and consultation services, enabling its clients to receive an array of one-stop health check services.
Etong Healthcare
Series B in 2017
EtongOnline Shanghai Medical Consulting provides third-party health management services to large and medium-sized enterprises in Shanghai, Beijing, Shenzhen, Guangzhou, Wuhan, & Chengdu. Its healthy management services include file recording, health assessment, health intervention, health education, health consultation, and private doctor services. The company also provides health examination services, such as employment health check, physical examination, PET-CT testing, gene detection, and enterprise welfare health check services. In addition, it offers medical services, such as medical guidance, specialist appointment, admission solutions, surgery appointment, secondary consultation, and particular examination arrangement services. Further, the company provides services in the areas of establishment of health infirmary, enterprise stratified health management, overseas medical, medical tourism, liability insurance, and oral care. EtongOnline Shanghai Medical Consulting was founded in 2009 and is headquartered in Shanghai City, China.
Hangzhou Yunhu Technology Group Co.,Ltd develops an Internet platform for primary medical services in China. It offers a series of platform-based testing products; and a SaaS based LIS\HIS platform, designed for local medication institutions. It also provides a third party cold chain logistic services to support the blood and drug delivery. The company was founded in 2017 and is based in Hangzhou, China.
Ins Health operates a comprehensive technology platform dedicated to innovating health insurance products. This platform integrates medical and insurance big data to enhance the risk assessment and competitiveness of health insurance offerings. Ins Health's model includes various components such as product innovation services, online intelligent underwriting, medical management, intelligent claims processing, and health management. The company has played a significant role in advancing mid-end medical insurance, million medical insurance, elderly cancer prevention insurance, and patient medical insurance. By establishing a micro-ecology framework for health insurance, Ins Health aims to streamline and improve the overall efficiency of health insurance processes.
Xiaolu Clinic is an online platform connecting traditional Chinese medicine providers with consumers. It offers online traditional Chinese medicine consultancy services for patients with chronic disease and those suffering from sub-optimal health, areas that traditional Chinese medicine might treat with herbal mixtures and dietary augmentation. Users can be evaluated by traditional Chinese medicine doctors and purchase herbal remedies online, as well as engage in treatment monitoring and post-treatment analysis. It also provides health management services for staff at big companies, including Baidu Inc., China Life Insurance (Group) Co., and Tencent Holdings Ltd. The Beijing-based company was founded in 2016.
Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.
Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, focused on developing digital diagnostic and therapeutic solutions for children at risk of developmental delays, including autism. The company's online application allows parents and caregivers to assess and monitor their child's cognitive development through a series of behavioral questions and a brief video recording of the child at play. This process generates scores and personalized recommendations, helping families understand their child's risk for developmental disorders and facilitating communication with healthcare providers. By utilizing responsible artificial intelligence, Cognoa aims to identify subtle signs of developmental delays and support informed clinical diagnoses. Its products are designed to be routinely prescribed by pediatricians and are intended to improve the standard of care for diagnosing and treating behavioral health conditions in children.
Shenzhen Easyhin Technology Co., Ltd. specializes in maternal and child health through its online application, Mommy Knows. Founded in 2014 and based in Shenzhen, China, the company provides a range of clinical services, including pediatric checkups, ENT care, nutrition, and dentistry. Easyhin combines cross-border healthcare with Internet technology, aiming to create innovative health management solutions for mothers and children. The company leverages expertise from seasoned professionals in the healthcare and technology sectors to develop its services. It has gained recognition for its mobile health management platform, which aims to deliver comprehensive health services conveniently to users, addressing various personal healthcare needs.
Private Equity Round in 2015
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
Developer of a medical assistant application software based on artificial intelligence technology. The company's application software provides users with private doctor services, and has now opened consulting services for obstetrics and gynecology and pediatrics, enabling users to have medical services remotely.
InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductor, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.
DNAtrix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in virus-driven immunotherapies for cancer treatment. The company develops modified viruses designed to selectively target and kill cancer cells, with its lead product, DNX-2401, focused on glioblastoma, an aggressive and currently incurable brain tumor. This oncolytic immunotherapy has shown promising early results, having been administered to over 35 patients. In addition to DNX-2401, DNAtrix is advancing other therapies, including DNX-2440 and DNX-2450 for solid tumors, and MYX-135 for hematological malignancies. The company aims to expand its platform technology to address a broader range of cancers, including brain metastases, ovarian, and pancreatic cancer. DNAtrix has formed a strategic partnership with Valo Therapeutics to enhance its research and development efforts.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
Cognoa, Inc. is a pediatric behavioral health company based in Palo Alto, California, focused on developing digital diagnostic and therapeutic solutions for children at risk of developmental delays, including autism. The company's online application allows parents and caregivers to assess and monitor their child's cognitive development through a series of behavioral questions and a brief video recording of the child at play. This process generates scores and personalized recommendations, helping families understand their child's risk for developmental disorders and facilitating communication with healthcare providers. By utilizing responsible artificial intelligence, Cognoa aims to identify subtle signs of developmental delays and support informed clinical diagnoses. Its products are designed to be routinely prescribed by pediatricians and are intended to improve the standard of care for diagnosing and treating behavioral health conditions in children.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...
Kindstar Global (Beijing) Technology, Inc. is a Chinese provider of specialty clinical testing services, primarily serving hospitals across the country, including tertiary care facilities. Founded in 2003 and headquartered in Wuhan, the company specializes in esoteric diagnostic testing and laboratory services. It also offers medical research, clinical trial services, and translational medicine studies to healthcare professionals and pharmaceutical companies. Kindstar Global is committed to developing advanced medical testing technologies and adheres to international standards and guidelines. The company operates laboratory facilities in major cities such as Beijing, Shanghai, and Wuhan, and maintains strategic partnerships, including one with ImmunArray, to enhance its service offerings.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
OriGene Technologies, Inc. specializes in the development, manufacturing, and sale of genome-wide research and diagnostic products tailored for academic, pharmaceutical, and biotechnology applications. Founded with a focus on creating a comprehensive collection of full-length human cDNAs, the company offers a diverse range of products, including cDNA clones, shRNA and siRNA tools, and CRISPR/Cas9 genome editing products. Additionally, OriGene provides proteins and lysates, an extensive array of antibodies for immunohistochemistry, and various assay kits, including ELISA and luminex kits. The company supports critical biological research by supplying essential resources for cancer biomarker studies, stem cell research, and other areas. With a commitment to facilitating gene-based research, OriGene distributes its products globally through distributors and online channels. Established in 1995 and based in Rockville, Maryland, OriGene continues to enhance its offerings to meet the evolving needs of researchers in the life sciences field.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
MetaCure Limited is a medical device company focused on developing and commercializing minimally invasive solutions for metabolic and gastric conditions, particularly type 2 diabetes. Founded in 2003 and headquartered in Hamilton, Bermuda, with an additional office in Düsseldorf, Germany, the company has created innovative products such as the DIAMOND system and Tantalus. These devices deliver electrical stimulation to the stomach during meals, promoting gastric contractions to help regulate blood glucose levels and provide an alternative to insulin treatments. MetaCure aims to address the growing prevalence of type 2 diabetes and obesity through its advanced therapeutic solutions, primarily targeting markets in the United States, Europe, and Asia.
HD Biosciences Inc. is a Shanghai-based biotechnology company that specializes in contract research for drug discovery. The company has developed a comprehensive range of technology platforms and expertise in areas such as assay development, high throughput drug screening, structure-activity relationship (SAR) studies, and hit-to-lead biology solutions. Additionally, it focuses on natural product-based lead discovery. HD Biosciences has established long-term research agreements with notable clients, including Pfizer and Organon, positioning itself as a leader in biology-based drug discovery in China. Its services encompass a variety of stages in the drug discovery process, from assay development and validation to hit identification and in vivo pharmacology, catering to the needs of pharmaceutical and biotech companies globally.
ViOptix, Inc. specializes in tissue oximetry technology that measures local tissue oxygen saturation. The company offers the T.Ox Tissue Oximeter, a portable unit featuring a color LCD touchscreen, which can operate with one or two channels and supports up to two fiber optic sensors. Its product line also includes Wi-Fi enabled T.Ox Remote Monitoring devices for wireless data transmission, one-time use T.Ox Small Patch sensors for continuous StO2 monitoring, and T.Ox Silicone Surround sensors for monitoring new flap applications. ViOptix's technology has applications across various fields, including plastic surgery, intraoperative and postoperative monitoring, wound healing assessment, detection of peripheral vascular disease, and critical care. Founded in 1999 and headquartered in Fremont, California, the company was previously known as Photonify Technologies, Inc. before rebranding in 2003. Its first product, the ODISsey System, received FDA clearance in 2005 for measuring localized tissue oxygenation in critical care settings.
The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...
ViOptix, Inc. specializes in tissue oximetry technology that measures local tissue oxygen saturation. The company offers the T.Ox Tissue Oximeter, a portable unit featuring a color LCD touchscreen, which can operate with one or two channels and supports up to two fiber optic sensors. Its product line also includes Wi-Fi enabled T.Ox Remote Monitoring devices for wireless data transmission, one-time use T.Ox Small Patch sensors for continuous StO2 monitoring, and T.Ox Silicone Surround sensors for monitoring new flap applications. ViOptix's technology has applications across various fields, including plastic surgery, intraoperative and postoperative monitoring, wound healing assessment, detection of peripheral vascular disease, and critical care. Founded in 1999 and headquartered in Fremont, California, the company was previously known as Photonify Technologies, Inc. before rebranding in 2003. Its first product, the ODISsey System, received FDA clearance in 2005 for measuring localized tissue oxygenation in critical care settings.